The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:2
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [41] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [42] Progression-free survival in oncology: Caveat emptor!
    Bergmann, Troels K.
    Christensen, Mette Marie H.
    Henriksen, Daniel P.
    Haastrup, Maija Bruun
    Damkier, Per
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (03) : 240 - 244
  • [43] The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
    Tizianel, Irene
    Caccese, Mario
    Torresan, Francesca
    Lombardi, Giuseppe
    Evangelista, Laura
    Crimi, Filippo
    Sepulcri, Matteo
    Iacobone, Maurizio
    Padovan, Marta
    Galuppini, Francesca
    Zagonel, Vittorina
    Scaroni, Carla
    Ceccato, Filippo
    CANCERS, 2022, 14 (16)
  • [44] Development and validation of a preoperative MRI-based radiomics nomogram to predict progression-free survival in patients with clival chordomas
    Zhai, Yixuan
    Bai, Jiwei
    Xue, Yake
    Li, Mingxuan
    Mao, Wenbin
    Zhang, Xuezhi
    Zhang, Yazhuo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05) : 345 - +
  • [46] Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer
    Ahn, Jinwoo
    Ahn, Dong-Won
    Park, Jaewoo
    Jung, Kwangrok
    Lee, Jong-Chan
    Hwang, Jin-Hyeok
    Jeong, Ji Bong
    Kim, Jaihwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1981 - 1988
  • [47] Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients
    Wichmann, Gunnar
    Lehmann, Claudia
    Herchenhahn, Cindy
    Kolb, Marlen
    Hofer, Mathias
    Wiegand, Susanne
    Dietz, Andreas
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [48] Concordance index: Surrogacy of progression-free survival for overall survival
    Fan, Yiwei
    Yin, Guosheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [49] Plasma Chromogranin A Levels Predict Survival and Tumor Response in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors
    Chou, Wen-Chi
    Chen, Jen-Shi
    Hung, Yu-Shin
    Hsu, Jun-Te
    Chen, Tse-Ching
    Sun, Chien-Feng
    Lu, Chang-Hsien
    Hwang, Tsann-Long
    ANTICANCER RESEARCH, 2014, 34 (10) : 5661 - 5669
  • [50] A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors
    Homps, Margaux
    Soyer, Philippe
    Coriat, Romain
    Dermine, Solene
    Pellat, Anna
    Fuks, David
    Marchese, Ugo
    Terris, Benoit
    Groussin, Lionel
    Dohan, Anthony
    Barat, Maxime
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2023, 189 (04) : 476 - 484